Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
IPI Legacy Liquidation Co Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
IPI Legacy Liquidation Co's earnings have been declining at an average annual rate of -23.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 118.6% per year.
Anahtar bilgiler
-23.8%
Kazanç büyüme oranı
116.8%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 118.6% |
| Özkaynak getirisi | n/a |
| Net Marj | -353.9% |
| Son Kazanç Güncellemesi | 30 Sep 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Investors Still Aren't Entirely Convinced By Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Revenues Despite 50% Price Jump
Apr 17
The Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 30Impel Pharmaceuticals Inc. (NASDAQ:IMPL) Analysts Just Slashed This Year's Revenue Estimates By 12%
Mar 26Impel NeuroPharma GAAP EPS of -$1.09 misses by $0.04, revenue of $2.8M misses by $1.04M
Aug 15Impel stock rises as dosing begins in mid-stage trial of INP105 for agitation in autistic people
Jul 19Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Jun 28Impel NeuroPharma reports Q1 results
Jun 07Gelir ve Gider Dağılımı
IPI Legacy Liquidation Co nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 23 | 21 | -74 | 77 | 4 |
| 30 Jun 23 | 19 | -92 | 81 | 7 |
| 31 Mar 23 | 15 | -109 | 80 | 11 |
| 31 Dec 22 | 13 | -106 | 78 | 11 |
| 30 Sep 22 | 8 | -108 | 77 | 15 |
| 30 Jun 22 | 5 | -102 | 74 | 18 |
| 31 Mar 22 | 2 | -92 | 65 | 20 |
| 31 Dec 21 | 1 | -77 | 51 | 21 |
| 30 Sep 21 | 0 | -66 | 36 | 25 |
| 30 Jun 21 | 0 | -50 | 22 | 25 |
| 31 Mar 21 | 0 | -48 | 19 | 26 |
| 31 Dec 20 | 0 | -46 | 17 | 28 |
Kaliteli Kazançlar: IMPL.Q is currently unprofitable.
Büyüyen Kar Marjı: IMPL.Q is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IMPL.Q is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.
Büyüme Hızlandırma: Unable to compare IMPL.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: IMPL.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Özkaynak Getirisi
Yüksek ROE: IMPL.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.